Meeting
2012 ASCO Annual Meeting
Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).
Authors
Franck E. Nicolini
Centre Hospitalier Lyon Sud, Pierre Bénite, France
Franck E. Nicolini , Jeffrey Howard Lipton , Hagop Kantarjian , Meir Wetzler , Luke Paul Akard , Michele Baccarani , Adam Craig , Nisha Nanda , Peter D. Brown , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00375219 and NCT00462943
Citation
J Clin Oncol 30, 2012 (suppl; abstr 6513)
DOI
10.1200/jco.2012.30.15_suppl.6513
Abstract #
6513
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Bcr-abl kinase domain mutations and resistance in ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.
First Author: Simona Soverini
Poster
2012 ASCO Annual Meeting
Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).
First Author: Meir Wetzler
Poster
2020 ASCO Virtual Scientific Program
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
First Author: Benjamin J. Solomon
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini